|

Anti-CD19/CD20/CD22 CAR T-Cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-CD19/20/22 Chimeric Antigen Receptor T-Cells, CD19/CD20/CD22-targeted CAR-T Cells

Pipeline

Phase 1: 1

Top Sponsors

  • Sumithira Vasu1

Indications

  • Refractory Childhood Non-Hodgkin Lymphoma1
  • Refactory Childhood Acute Lymphoblastic Leukemia1
  • Refractory Indolent Non-Hodgkin Lymphoma1
  • Refractory B-Cell Prolymphocytic Leukemia1
  • Recurrent Indolent Non-Hodgkin Lymphoma1

Columbus, Ohio1 trial

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Nationwide Children's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.